Comprehensive Genomic Analysis Reveals Key Metastatic Pathways and Drug Targets in Thyroid Cancer
Key Insights
Researchers identified 110 common genes driving metastasis across four thyroid cancer (search) subtypes using genetically engineered mouse models, revealing shared pathways despite different genetic mutations.
The study uncovered critical metastatic mechanisms including inflammatory cytokine production, platelet aggregation through Tbxas1 (search) overexpression, and immune evasion via PD-L1 (search) and Mertk (search) upregulation.
Low-dose aspirin significantly reduced lung metastases by 73% in mouse models, while combination therapy targeting BRAF (search) and β-catenin (search) pathways showed synergistic effects against treatment-resistant metastatic cells.
A comprehensive genome-wide transcriptome analysis has identified critical genes and pathways driving thyroid cancer (search) metastasis, revealing potential drug targets that could transform treatment approaches for advanced disease. The study, conducted using genetically engineered mouse models representing the full spectrum of thyroid carcinogenesis, provides unprecedented insights into the molecular mechanisms underlying metastatic progression.
Comprehensive Analysis Across Thyroid Cancer Subtypes
Researchers established metastatic cell lines from four distinct thyroid cancer (search) types: papillary thyroid carcinoma (search) (PTC) with BrafV600E mutation, follicular thyroid carcinoma (search) (FTC) with KrasG12D mutation, poorly differentiated thyroid carcinoma (search) (PDTC) with KrasG12D and Cdkn2anull mutations, and anaplastic thyroid carcinoma (search) (ATC) with BrafV600E and Trp53null mutations. Through successive rounds of tail vein injection and lung metastasis isolation, they enriched for highly metastatic cell populations designated as Met2 cells.
The transcriptome analysis identified 88 up-regulated and 22 down-regulated genes present across all four Met2 cell lines, despite their different underlying genetic drivers. This approach significantly reduced the number of differentially expressed genes from over 2,200 in each cell line to 110 common genes, increasing efficiency for drug target identification.
Key Metastatic Pathways Revealed
Gene ontology and pathway analysis revealed that regulation of cytokine production, inflammatory and negative regulation of immune response, neutrophil migration and phagocytosis, and cytokine- or receptor-mediated pathways were the top enriched ontology clusters. Protein-protein interaction network analysis identified 18 hub genes, with TNF (search) showing the highest degree of connectivity (47 interactions).
Critically, four hub genes (Tnf (search), Nckap1, Nlrp3, and Card11) were associated with poor disease-specific survival when analyzing thyroid carcinoma patient data from The Cancer Genome Atlas (TCGA, n=498). These genes are involved in inflammation and epithelial-mesenchymal transition pathways, indicating their crucial role in thyroid cancer (search) metastases.
Inflammatory Cytokine Production and Immune Evasion
Met2 cells demonstrated significantly increased production of inflammatory cytokines and chemokines, including CSF1, CSF2, CSF3, CCL2, CCL11, CXCL5, IL-1α, and IL-6. These factors are known to promote tumor cell immune escape and metastasis by recruiting tumor-associated macrophages, myeloid-derived suppressor cells, tumor-associated neutrophils, and regulatory T cells.
The study confirmed increased expression of IL-6 and IL-6 receptor in Met2 cells through Western blot analysis. Additionally, all Met2 cell lines overexpressed immune checkpoint regulators CD274 (search) (PD-L1 (search)) and CD52, along with Mertk (search), a receptor tyrosine kinase that activates multiple signaling pathways to promote tumor cell migration, immune escape, and cancer stem cell transformation.
Platelet Aggregation and Metastatic Niche Formation
A particularly significant finding was the overexpression of Tbxas1 (search) (thromboxane A synthase 1) in Met2 cells, which catalyzes the conversion of prostaglandin H2 to thromboxane A2 (TXA2), a potent inducer of platelet aggregation. This discovery provided a mechanistic explanation for the significant red blood cell infiltration observed in pre-metastatic lung niches.
To validate this pathway's therapeutic relevance, researchers treated mice with low-dose aspirin, an irreversible inhibitor of TXA2. The treatment significantly reduced both the size and number of lung metastatic foci (6.8 ± 1.5 vs 25 ± 3.4, p<0.01) after intravenous injection of metastatic cells, confirming Tbxas1 (search)'s role in promoting platelet aggregation and metastatic niche formation.
Cancer Stem Cell Features and Drug Resistance
Met2 cells exhibited characteristics of cancer stem cells, including overexpression of LBH (Limb-Bud-and-Heart), a WNT/β-catenin (search) target required for mammary stem cell self-renewal. Flow cytometry analysis revealed increased CD44 and decreased CD24 expression in Met2 cells, indicating transformation to or enrichment of cancer stem cells.
Functional assays demonstrated that Met2 cells showed enhanced tumorsphere formation, which was significantly reduced (>70%) after treatment with β-catenin (search) inhibitor PKF118-310 (search). Importantly, Met2 cells displayed resistance to BRAFV600E inhibitor PLX4720, with only 10% reduction in tumorsphere formation in BVE-Met2 cells and no reduction in BVETrp53null-Met2 cells.
Combination Therapy Shows Promise
Colony formation assays revealed that BVE-Met2 cells formed significantly more colonies at low seeding numbers (19.7 ± 1.2 vs 11.3 ± 1.7, p<0.05) and showed resistance to PLX4720. However, both primary and metastatic cells remained sensitive to PKF118-310 (search). Notably, combination therapy with low doses of PLX4720 and PKF118-310 showed synergistic effects, enhancing apoptosis from 8.8% to 93.1% in BVE cells and from 7% to 65.2% in BVE-Met2 cells.
Clinical Implications and Future Directions
The study's findings have immediate clinical relevance, as several identified targets have corresponding FDA-approved therapies. IL-6 antibody siltuximab, IL-6 receptor antibody tocilizumab, JAK1 (search)/2 kinase inhibitor ruxolitinib, and PD-L1 (search) antibodies are already available. The research suggests that simultaneously targeting both PD-1/PD-L1 and IL-6/JAK1 pathways may be more effective than single-agent therapy.
For platelet aggregation targeting, while aspirin showed efficacy, the selective TXA2 receptor antagonist Ifetroban is currently under Phase II clinical trial (NCT03694249) for metastatic cancer treatment, potentially offering better tolerability. Additionally, several Axl/Mer inhibitors, including INCB081776 and PF-07265807, are in Phase I clinical trials for advanced solid tumors.
The research demonstrates that metastatic thyroid cancer (search) cells utilize multiple synchronized pathways to promote inflammation, cytokine storm, platelet aggregation, and pre-metastatic niche formation. Given the extensive cross-interactions among these pathways, the authors suggest that combinational therapy targeting PD-L1 (search), Tbxas1 (search), and IL-6 may offer superior therapeutic outcomes compared to single-agent approaches.
This comprehensive analysis provides a roadmap for developing more effective treatments for metastatic thyroid cancer (search), moving beyond traditional approaches to precision medicine based on molecular profiling and pathway-specific targeting.